Abstract:T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-refractory T-cell malignancy with limited therapeutic options and a poor prognosis. Current disease concepts implicate TCL1A oncogene-mediated enhanced T-cell receptor (TCR) signaling and aberrant DNA repair as central perturbed pathways. We discovered that recurrent gains on chromosome 8q more frequently involve the argonaute RISC catalytic component 2 (AGO2) gene than the adjacent MYC locus as the affected minimally amplified genomic region. AGO2 has been understood as a protumorigenic key regulator of miRNA (miR) processing. Here, in primary tumor material and cell line models, AGO2 overrepresentation associated (i) with higher disease burden, (ii) with enhanced in vitro viability and growth of leukemic T cells, and (iii) with miR-omes and transcriptomes that highlight altered survival signaling, abrogated cell-cycle control, and defective DNA damage responses. However, AGO2 elicited also immediate, rather non-RNA-mediated, effects in leukemic T cells. Systems of genetically modulated AGO2 revealed that it enhances TCR signaling, particularly at the level of ZAP70, PLCγ1, and LAT kinase phosphoactivation. In global mass spectrometric analyses, AGO2 interacted with a unique set of partners in a TCR-stimulated context, including the TCR kinases LCK and ZAP70, forming membranous protein complexes. Models of their three-dimensional structure also suggested that AGO2 undergoes posttranscriptional modifications by ZAP70. This novel TCR-associated noncanonical function of AGO2 represents, in addition to TCL1A-mediated TCR signal augmentation, another enhancer mechanism of this important deregulated growth pathway in T-PLL. These findings further emphasize TCR signaling intermediates as candidates for therapeutic targeting. Significance: The identification of AGO2-mediated activation of oncogenic T cells through signal amplifying protein-protein interactions advances the understanding of leukemogenic AGO2 functions and underlines the role of aberrant TCR signaling in T-PLL.

Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment

Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene

Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL

Epigenetic Alteration Contributes to the Transcriptional Reprogramming in T-cell Prolymphocytic Leukemia

T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H)

Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia: a single-institution experience

Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling

High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia

Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia

T-Cell Prolymphocytic Leukemia with T(x;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.

Mature T-cell Leukemia Primarily Involving Blood and Bone Marrow without TCL1 or MTCP1 Rearrangement: A Subtype of T-Prolymphocytic Leukemia or a Distinct Entity?

A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia

Pharmacologic interception in T-cell leukemia 1A associated pathways as a treatment rationale for chronic lymphocytic leukemia

Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia

Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Morphology, immunophenotype, and suggested diagnostic criteria of TCL1 family–negative T-prolymphocytic leukemia

T‐cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments